Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH

 
• By Joseph Haas
  
Employee or Marketing teams are jointly meta Analysis of strengths, weaknesses and product. Including brainstorming to plan for cooperation
Metacrine is changing course to a focus on IBD, rather than NASH
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business